Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:6
  • preuzimanja u poslednjih 30 dana:2
članak: 1 od 144  
Back povratak na rezultate
Vojnosanitetski pregled
2020, vol. 77, br. 4, str. 426-430
jezik rada: engleski
vrsta rada: kratki članak
objavljeno: 14/05/2020
doi: 10.2298/VSP170629083T
Creative Commons License 4.0
Imunohistohemijska ekspresija androgenih receptora kod karcinoma prostate i benigne hiperplazije prostate
aUniverzitet u Novom Sadu, Medicinski fakultet, Katedra za patologiju + Klinički centar Vojvodine, Centar za patologiju i histologiju, Novi Sad
bUniversity of Novi Sad, Faculty of Medicine, Department of surgery + Klinički centar Vojvodine, Klinika za urologiju, Novi Sad
cKlinički centar Vojvodine, Centar za patologiju i histologiju, Novi Sad + Univerzitet u Novom Sadu, Medicinski fakultet, Katedra za histologiju i embriologiju

e-adresa: sandra.trivunic-dajko@mf.uns.ac.rs

Sažetak

Uvod/Cilj. Karcinom prostate (PCa), kao i njegov ishodišni organ se nalaze pod uticajem hormona, što je iskorišćeno u terapijske svrhe. Androgeni preko androgenih receptora (AR) utiču na ćelijski rast i funkciju, proliferaciju, diferencijaciju, apoptozu, lipidni metabolizam i sekretornu aktivnost prostate, ali i na razvoj i progresiju PCa. Antiandrogena terapija se sprovodi kod bolesnika sa metastaskim PCa, upravo sa ciljem da blokira dejstvo androgena. Imunohistohemijskom analizom AR u tkivu prostate sa karcinomom, možemo da pretpostavimo kako će tumor reagovati na datu antiandrogenu terapiju, bilo da se radi o androgen pozitivnim ili androgen negativnim, rezistentnim tumorima. Saznanja o zastupljenosti AR u tkivu tumora mogla bi poslužiti kao prognostički indikator u patohistološkoj analizi. Cilj rada je bio evaluacija ekspresije AR kod bolesnika sa benignom hiperplazijom (BHP) i kod bolesnika sa PCa, pre sprovedene terapije. Metode. Imunohistohemijska analiza je sprovedena uz upotrebu anti-human AR monoclonal antibody AR441 (DAKO), uz semikvantitativnu procenu prisustva i inteziteta AR kod 195 bolesnika, 165 sa BHP i 30 sa PCa. Materijal je dobijen iglenom biopsijom ili transuretralnom resekcijom prostate (TURP). Rezultati. Sve sekretorne ćelije kod bolesnika sa BHP su bile intezivno androgen pozitivne, dok su kod bolesnika sa PCa, mahom bile umereno do izrazito pozitivne, ali sa fokusima negativnosti. Uočena je negativna korelacija AR sa Gleason skorom i International Society of Urologic Pathology (ISUP) gradus grupom PCa, koja nije bila statistički značajna. Zaključak. Rezultati studije su pokazali da je PCa, pre sprovedene terapije, androgen zavisan sa visokim stepenom ekspresije AR.

Ključne reči

Reference

Novododat članak: provera, normiranje i linkovanje referenci u toku.
Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25(2): 276-308
Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Molecular biology and physiology of the prostate. In: Berman DM, editor. Campbell-Walsh Urology. 10th ed. Philadelphia, PA: WB Saunders; 2011
Poelaert F, Van Praet C, Beerens AS, De Meerleer G, Fonteyne V, Ost P, et al. The role of androgen receptor expression in the curative treatment of prostate cancer with radiotherapy: a pilot study. Biomed Res Int 2015; 2015: 812815
Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972; 22(4): 232-40
Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Hormonal therapy for prostate cancer. In: Berman DM, editor. Campbell-Walsh Urology. 10th ed. Philadelphia, PA: WB Saunders; 2011
Horwich A, Parker C, de Reijke T, Kataja V. ESMO Guidelines Working Group. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl 6): vi106-14
Vojinov S, Levakov I, Jeremić D, Živojinov S, Marušić G. Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade. Vojnosanit Pregl 2011; 68(4): 321-6. (Serbian)
Hansson J, Abrahamsson PA. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol 2001;12(Suppl 2): S145-52
Wetherill YB, Petre CE, Monk KR, Puga A, Knudsen KE. The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. Mol Cancer Ther 2002; 1(7): 515-24
Hudes GR. Signaling inhibitors in the treatment of prostate cancer. Invest New Drugs 2002; 20(2): 159-72
Noordzij MA, Bogdanowicz JF, van Krimpen C, van der Kwast TH, van Steenbrugge GJ. The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients. Department of Urology, Erasmus University, Rotterdam, Netherland. J Urol 1997; 158(5): 1880-4; discussion 1884-5
Bortticelli AR, Pitino A, Botticelli D. Expression of neuroendocrine cells, androgen receptors and angiogenesis in prostate carcinoma. Pathologica 2002; 94(2): 107-11
Renzo A, Botticelli A, Pitino A, Botticelli AR, Zaffe D. Prognostic relationship between immunohistochemical expression of neuroendocrine cells, androgen receptors and angiogenesis in prostate carcinoma. Pathologica 2002; 94(2): 109-12
Qui YQ, Lauschner I, Braun PM. Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review: Asian J Androl 2008; 10(6): 855-63
World Health Organization. World Health Statistics 2016: Monitoring health for the SDGs. Available from: www.who.int/gho/publications/world_health_statistics/2016/en
Zhou M, Netto G, Epstein J. Uropathology: High-yerld pathology. Philadelphia, PA: Elsevier, Saunders; 2012
Trivunić S, Budakov P, Vučković N, Živojinov M. Morphological parameters of prostatic adenocarcinoma. Med Pregl 2007; 60(11-12): 549-52
Wilkström P, Marusic J, Stattin P, Bergh A. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate carcinoma. Prostate 2009; 69(8): 799-809
Li R, Weeler T, Dai H, Frlov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathological feature and decreased biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004; 28(7): 928-34
Tamburrino L, Salvianti F, Marchiani S, Pinzani P, Nesi G, Serni S, et al. Androgen receptor (AR) expression in prostate cancer and progression of the tumor: Lessons from cell lines, animal models and human specimens. Steroids 2012; 77(10): 996-1001
Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009; 16(6): 458-62
Hanahan D, Weinberg A. Hallmark of cancer: the next generation. Cell 2011; 144(5): 646-74
Tadeka H, Akakura K, Masai M, Akimoto S, Yatani R, Shimazaki J. Androgen receptor content of the prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 1996; 77(5): 934-40
Segawa N, Mori I, Utsunomiya H, Nakamura M, Nakamura Y, Shan L, et al. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathol Int 2001; 51(6): 452-9
Theodoropoulos VE, Tsigka A, Mihalopoulou A, Tsoukala V, Lazaris AC, Patsouris E, et al. Evaluation of the neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. Urology 2005; 66(4): 332-7
Osman WM, Abd El Atti RM, Abou Gabal HH. DJ-1 and androgen receptor immunohistochemical expression in prostatic carcinoma: a possible role in carcinogenesis. J Egypt Natl Canc Inst 2013; 25(4): 223-30
Gordetsky J, Epstein J. Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagn Pathol 2016; 11: 25